March 11, 2025 Barclays 27th Annual Global Healthcare Conference, Miami Beach, FL Fireside chat: March 12, 2025, from ...
Nurix Therapeutics, Inc. is a San Francisco based early clinical-stage biotechnology concern focused on leveraging its expertise in cellular protein modulation to develop therapies against ...
About Nurix Therapeutics, Inc. Nurix Therapeutics is ... Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and ...
Zacks Investment Research on MSN1d
Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...
About Nurix Therapeutics, Inc. Nurix Therapeutics is ... Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback